

## DISCLOSURES:

Appropriate faculty disclosures will be made at the program.

The planners of this activity have nothing to disclose.

AdventHealth's CPD Committee members have no financial relationships with any proprietary entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients.

Maryam Kashi, DO, a member of the CPD Committee has relationships with Allergan/Ironwood and Synergy as part of their Speaking Bureau.

## NCCN GUIDELINES:

The National Comprehensive Cancer Network (NCCN) guidelines are considered in discussion of treatment options for cases presented at this conference.

AdventHealth is committed to making its activities accessible to all individuals.

If you have a disability, please submit a description of your needs, along with your registration, to assure that you will be able to participate in the activity.

## PRESENTED BY:

**AdventHealth Cancer Institute**

## SPONSORED BY:



AdventHealth Orlando is accredited by Florida Medical Association to provide continuing medical education for physicians. AdventHealth Orlando designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.



# *Immunotherapy: The 4th Armamentarium in the Care of Head and Neck Cancer Patients*

**KEYNOTE SPEAKER**

**SARA PAI, MD, PhD**

**THURSDAY, April 25, 2019**

**6:15 pm - 8:30 pm | THE ALFOND INN | WINTER PARK**

## PRESENTED BY:

**AdventHealth Cancer Institute**

## SPONSORED BY:



### KEYNOTE SPEAKER

**SARA PAI, MD, PhD**

Associate Professor, Surgery  
Harvard Medical School  
Associate Surgeon  
Massachusetts General Hospital  
Boston, MA

### MODERATOR & WELCOME REMARKS

**BRUCE HAUGHEY, MBChB, MS, FRACS, FACS**

Head and Neck Oncologic and Reconstructive Surgeon  
Florida ENT Surgical Specialists  
Medical Director, Oncology  
AdventHealth Cancer Institute  
Celebration, FL

### “MEET THE PROFESSORS” - PANEL DISCUSSION & CASE PRESENTATION

**J. SCOTT MAGNUSON, MD**

Chief Medical Officer, AdventHealth Nicholson Center  
Professor of Otolaryngology Head and Neck Surgery  
University of South Florida College of Medicine  
Medical Director, Head and Neck Surgery  
Co-Medical Director, Head and Neck Program  
AdventHealth Cancer Institute  
Celebration, FL

**SHRAVAN KANDULA, MD**

AdventHealth Medical Group  
Radiation Oncology at Central Florida  
AdventHealth Cancer Institute  
Orlando, FL

**TAREK M. MEKHAIL, MD, MSc, FRCSI, FRCSEd**

Associate Medical Director  
Medical Director, Thoracic Cancer Program  
AdventHealth Cancer Institute  
Associate Professor  
University of Central Florida  
Orlando, FL

**INTENDED AUDIENCE:** All physicians, especially: Otolaryngologists, Dentists, Thoracic Oncologists, NeuroOncologists, Medical Oncologists, Radiation Oncologists, Surgical Oncologists, General Surgeons, Plastic Surgeons, Oral Surgeons, Radiologists, Pathologists, Hematology Oncologists, Family Medicine, Internal Medicine, Psychiatrists, Physician Assistants, Nurse Practitioners, and Other Health Care Professionals.

## *Immunotherapy:*

### *The 4th Armamentarium in the Care of Head and Neck Cancer Patients*

**DATE:** Thursday, April 25, 2019

**LOCATION:** The Alford Inn  
300 East New England Avenue  
Winter Park, FL 32789  
(407) 998-8090

**TIME:** Registration | Reception | Exhibit Hall

6:15 - 7:00 pm

Dinner & Program

7:00 - 8:30 pm

**Moderator & Welcome Remarks:**

Bruce Haughey, MBChB, MS, FRACS, FACS

**Keynote Speaker:**

Sara Pai, MD, PhD

"Meet the Professors" - Panel Discussion  
Case Presentation

**RSVP:** By Monday, April 22, 2019  
Phone: 407-303-1945  
FHCI.Registration@AdventHealth.com

Business Attire  
Valet Parking Complimentary

### **EDUCATIONAL OBJECTIVES:**

1. Discuss the design and results of the pivotal immunotherapy clinical trials performed in head and neck cancer patients.
2. List 3 potential mechanisms of resistance and/or non-response to immunotherapy.
3. Describe 2 strategies to improve response rates to immunotherapy.